Real-World Treatment Patterns and Outcomes by Line of Therapy and Race in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated in the United States: Results From the Final Analysis of the Prospective, Observational, informCLL Registry.
Nilanjan GhoshJeff P SharmanMeghan GutierrezWasiulla KhanZaina P QureshiAnat RazVincent GirardiGabriel S KrigsfeldJacqueline C BarrientosPublished in: Clinical lymphoma, myeloma & leukemia (2024)
In this prospective, large, real-world CLL registry, first-line ibrutinib was associated with longer TTNT than chemoimmunotherapy, with sustained benefit up to 4 years of follow-up.